The agreements, finalized between May and July 2026, fundamentally shift the company’s repayment timeline. The deal with JGB Capital extends the maturity of existing debentures by one year to April 15, 2028, while revising the amortization schedule. Simultaneously, the AXA agreement replaces previous repayment terms with a new schedule of minimum annual payments, pushing the maturity date to December 31, 2029.

CEO Damien Lamendola framed the restructuring as a necessary alignment of capital structure with ongoing business needs. By freeing up over $26 million in cash through 2027, the company aims to prioritize its Marpai Saves initiative and accelerate the expansion of its pharmacy benefit management and third-party administration platforms. This flexibility is intended to support market share growth and long-term enterprise stability without immediate liquidity constraints.